This Phase 3 protocol is a randomized, double-blind, study evaluating the safety and efficacy of switching from a regimen of either dolutegravir (DTG) and emtricitabine (Emtriva®)/tenofovir alafenamide (Descovy®; F/TAF) or DTG and emtricitabine/tenofovir disoproxil fumarate (Truvada®; F/TDF) to a fixed dose combination (FDC) of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus DTG+F/TAF in virologically suppressed HIV-1 infected adults with or without antiretroviral resistance. Male and female HIV-1 infected patients greater than or equal to 18 years of age currently receiving an ARV regimen of DTG+F/TAF or DTG+F/TDF may be eligible to participate in this study.
University of South Carolina School of Medicine
Two Medical Park, Suite 502
Columbia, SC 29203
Study Site Principal Investigator Contact Information:
Helmut Albrecht, MD at 803-540-1000